RecoverPC: A Phase 2 Study of RElugolix versus GnRH agonist quality of life (QOL) and testosterone reCOVERy in men with Prostate Cancer (DF/HCC 22-599)
This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. The drugs are already standard treatment for people with prostate cancer, and the drugs will be used as described in their label.
The names of the study drugs involved in this study are:
- Leuprolide (type of ADT)
- Relugolix (type of ADT)
Contact
Clinical Trials Office at [email protected] or (203) 358-8879.
Principal Investigator(s)
Anthony Gulati, MD
Sponsor(s)
Dana-Farber Cancer Institute
Location
Bennett Cancer Center
Stamford, CT 06902
Main: 203-358-8879